Nasopharyngeal (nay-zoh-fuh-RIN-jee-ul) carcinoma bụ ọrịa kansa nke na-eme na nasopharynx, nke dị n'azụ imi na n'elu azụ nke akpịrị gị.
Nasopharyngeal carcinoma dị ụkọ na United States.Ọ na-eme ọtụtụ ugboro n'akụkụ ụwa ndị ọzọ - kpọmkwem Ndịda Ebe Ọwụwa Anyanwụ Eshia.
Nasopharyngeal carcinoma siri ike ịchọpụta n'oge.Nke ahụ bụ eleghị anya n'ihi na nasopharynx adịghị mfe inyocha na mgbaàmà nke nasopharyngeal carcinoma na-eṅomi nke ndị ọzọ, ndị na-ahụkarị ọnọdụ.
Nasopharyngeal carcinoma na-emekarị n'etiti ndị agadi na ndị agadi karịrị afọ 40, ma nwee àgwà doro anya na mpaghara na ezinụlọ, ọnụ ọgụgụ na-eme na Guangdong bụ nke mbụ na China, nke a makwaara dị ka "ọrịa cancer Guangdong".
1. Ntuziaka maka nchọpụta na ọgwụgwọ nke nasopharyngeal carcinoma
N'ime ntuziaka 2021 maka nchọpụta na ọgwụgwọ nke nasopharyngeal Carcinoma, Chinese Society of Clinical Oncology (CSCO) gụnyere ụzọ nchọpụta serological na klas nke mbụ maka nchọpụta nke nasopharyngeal carcinoma, ma rụtụ aka na nchikota EB-VCA-IgA. na EB-NA1-IgA nje nje nje EB-IgA nwere ike ịbawanye ọnụọgụ nrịanrịa nke ọrịa kansa nasopharyngeal site na ugboro 3 (21% ~ 79%) wee belata ohere nke ọnwụ site na 88%!Nkwenye ndị ọkachamara 2019 na ngwa ụlọ ọgwụ nke akara maka nasopharyngeal Carcinoma gosikwara na EBV-EA-IgA bụ akara nke ọrịa EBV na-adịbeghị anya ma ọ bụ mmụba na-arụ ọrụ nke EBV, nke nwere ọkwa dị elu, a na-ejikarị ya eme ihe maka nyocha ọrịa cancer nasopharyngeal. na nchọpụta mmalite.
Ọmụmụ ihe ahụ na-egosi na nchọpụta atọ jikọtara EBV-VCA-IGA, EBV-EA-IGA na EB-NA1-IgA na-ekpuchi EBV gene spectrum, nke na-eme ka nghọta na nkọwapụta nke nchọpụta carcinoma nasopharyngeal, na-ebelata nchọpụta efu, na-eme ka ọ dị mma. izi ezi nke amụma ọrịa, ma buru amụma na ọ ga-eme ọrịa afọ 5-10 tupu oge eruo, nke kwesịrị ekwesị maka nyocha ọrịa cancer nasopharyngeal buru ibu.
2.VCA-IgA + EA-IgA + NA1-IgA nke Beijing Beier mepụtara nwere ike inye usoro nchọpụta mmalite maka Nasopharyngeal Carcinoma.
Magnetism gụnyere usoro immuno chemistry luminescence
| Aha ngwaahịa | Mbiri |
| EB nje VCA-IgA ngwa nchọpụta mmadụ | EB-VCA-IgA |
| EB nje EA-IgA ngwa nchọpụta ihe mgbochi | EB-EA-IgA |
| EB nje NA1-IgA ngwa nchọpụta mmadụ | EB-NA1-IgA |
Usoro Elisa:
| Aha ngwaahịa | Mbiri |
| EB nje VCA-IgA Elisa ngwa | EB-VCA-IgA |
| EB nje EA-IgA Elisa ngwa | EB-EA-IgA |
| EB nje NA1-IgA Elisa kit | EB-NA1-IgA |
3.Product Performance
Ngwa ule VCA-IgA nke Beijing Beier mepụtara nwere ike dochie ngwa ọkọlọtọ EU maka nchọpụta mmalite na nyocha nke carcinoma nasopharyngeal.
Akwụkwọ akụkọ ahụike Britain (BMJ) (ihe mmetụta 16.378) bụ otu n'ime akwụkwọ akụkọ ahụike anọ kachasị n'ụwa.N'afọ 2017, otu ndị nchọpụta bipụtara akwụkwọ na British Medical Journal (BMJ) "Nnyocha nke ngwa VCA-IgA ELISA asaa maka nchọpụta nke nasopharyngeal carcinoma na China: ikpe ikpe ikpe".
N'akwụkwọ a, ndị ọrịa 200 nwere carcinoma nasopharyngeal nasopharyngeal (NPC) na 200 normal serum sample (SYSUCC) sitere na Sun Yat-sen University Cancer Center ka a mụrụ ma nwalee, na arụmọrụ nke EB-VCA-IgA (ELISA) kits mepụtara site na 8. atụnyere ndị na-emepụta ika n'ahịa ụlọ maka nyocha arụmọrụ.Nkwubi okwu bụ na ngwa EBV-VCA-IgA (ELISA) nke Beijing Beier mepụtara nwere otu mmetụta nyocha dị ka EBV-VCA-IgA (ELISA) nke onye na-ebubata reagent Oumeng mepụtara, yana EBV-VCA-IgA (ELISA). ngwa nke Beijing Beier mepụtara nwere ike dochie ngwa a na-ebubata maka nchọpụta mmalite na nyocha nke carcinoma nasopharyngeal.E gosipụtara ozi nke ndị na-emepụta ika na-ekere òkè na ule a na Tebụl 1, egosipụtara nsonaazụ ule na tebụl 2, na nkwubi okwu ule gosipụtara na tebụl 3.
Nnwale mmechi
Atọ recombinant VCA-IgA kits-BB,HA na KSB- nwere diagnostic mmetụta hà na nke ọkọlọtọ kit.Ha nwere ike dochie maka ọkọlọtọ kit na ha nchikota nwere ike iji na mmalite nchọpụta nke na screening maka NPC.
Oge nzipu: Feb-23-2023